First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Sees Significant Drop in Short Interest

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) saw a large decrease in short interest in February. As of February 15th, there was short interest totalling 700 shares, a decrease of 41.7% from the January 31st total of 1,200 shares. Based on an average daily volume of 2,800 shares, the short-interest ratio is currently 0.3 days.

First Trust Nasdaq Pharmaceuticals ETF Price Performance

NASDAQ:FTXH traded down $0.06 on Monday, reaching $28.18. The stock had a trading volume of 2,226 shares, compared to its average volume of 3,226. The company has a market cap of $15.50 million, a price-to-earnings ratio of 20.07 and a beta of 0.63. The firm’s fifty day moving average is $27.41 and its two-hundred day moving average is $28.13. First Trust Nasdaq Pharmaceuticals ETF has a 12-month low of $25.73 and a 12-month high of $29.72.

First Trust Nasdaq Pharmaceuticals ETF Increases Dividend

The company also recently announced a dividend, which was paid on Tuesday, December 31st. Shareholders of record on Friday, December 13th were issued a $0.1304 dividend. This is a positive change from First Trust Nasdaq Pharmaceuticals ETF’s previous dividend of $0.13. The ex-dividend date was Friday, December 13th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. LPL Financial LLC increased its stake in shares of First Trust Nasdaq Pharmaceuticals ETF by 9.3% during the 4th quarter. LPL Financial LLC now owns 55,876 shares of the company’s stock valued at $1,507,000 after acquiring an additional 4,776 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in shares of First Trust Nasdaq Pharmaceuticals ETF by 17.0% during the 4th quarter. Envestnet Asset Management Inc. now owns 16,403 shares of the company’s stock valued at $442,000 after acquiring an additional 2,384 shares during the last quarter. Summit Investment Advisors Inc. increased its stake in shares of First Trust Nasdaq Pharmaceuticals ETF by 13.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 14,173 shares of the company’s stock valued at $382,000 after acquiring an additional 1,633 shares during the last quarter. Finally, Vivaldi Capital Management LP increased its stake in shares of First Trust Nasdaq Pharmaceuticals ETF by 15.6% during the 4th quarter. Vivaldi Capital Management LP now owns 8,677 shares of the company’s stock valued at $243,000 after acquiring an additional 1,171 shares during the last quarter.

First Trust Nasdaq Pharmaceuticals ETF Company Profile

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.